- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
Opinion
Video
Expert Perspectives on EVRIANCE clinical trial data
Andrew Weinstein, MD, MPH, FAAD and Jonathan S Zager, MD, FACS, FSSO explore the potential rationale behind observed variations in the and GLI and PTCH expression data within the EVRAINCE trial and comment on potential factors contributing to bias within the study.
Jonathan S Zager, MD, FACS, FSSO
Moffitt Cancer Center
Tampa, Florida
Lilia Correa-Selm, MD, FAAD, FACMS
Moffitt Cancer Center
Tampa, Florida
Aaron Farberg, MD
Bare Dermatology
Dallas, Texas
John Strasswimmer, MD, PhD
Florida Atlantic University
Delray Beach, Florida
Andrew Weinstein, MD, MPH, FAAD
Boynton Beach Skin, University of Miami
Boynton Beach and Coral Gables, Florida
Series Description: Experts in dermatology discuss the clinical trial data from the BOLT and EVRIANCE clinical trials and review patient cases related to the management of patients with locally advanced basal cell carcinoma treated with sonidegib and vismodegib.
Segment Description: Andrew Weinstein, MD, MPH, FAAD and Jonathan S Zager, MD, FACS, FSSO explore the potential rationale behind observed variations in the and GLI and PTCH expression data within the EVRAINCE trial and comment on potential factors contributing to bias within the study.
